and carvedilol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.celecoxibcelecoxib decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.celiprololsilodosin and celiprolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.choline magnesium trisalicylatecholine magnesium trisalicylate decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.clarithromycinclarithromycin will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.clevidipinesilodosin and clevidipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.clotrimazoleclotrimazole will decrease the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.crizotinibcrizotinib increases levels of silodosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.crizotinib increases levels of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.deferasiroxdeferasirox will decrease the level or effect of silodosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.diclofenacdiclofenac decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.diflunisaldiflunisal decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.diltiazemdiltiazem will increase the level or effect of silodosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.silodosin and diltiazem both increase anti-hypertensive channel blocking. Use Caution/Monitor.doxazosindoxazosin and silodosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.dronedaronedronedarone will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.elagolixelagolix will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.eliglustateliglustat increases levels of silodosin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.enalaprilenalapril, silodosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.erythromycin baseerythromycin base will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.erythromycin ethylsuccinateerythromycin ethylsuccinate will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.erythromycin lactobionateerythromycin lactobionate will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.erythromycin stearateerythromycin stearate will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.esmololsilodosin and esmolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. Increased risk of dizziness and orthostatic hypotension when silodosin is administered concurrently with antihypertensives.etodolacetodolac decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.felodipinefelodipine will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.silodosin and felodipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.fenoprofenfenoprofen decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.flurbiprofenflurbiprofen decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.fluvoxaminefluvoxamine will increase the level or effect of silodosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fosinoprilfosinopril, silodosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.fosphenytoinfosphenytoin will decrease the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.glecaprevir/pibrentasvirglecaprevir/pibrentasvir will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.ibuprofenibuprofen decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.ibuprofen IVibuprofen IV decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.iloperidoneiloperidone increases effects of silodosin by pharmacodynamic synergism. Use Caution/Monitor.imidaprilimidapril, silodosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.indinavirindinavir will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.indomethacinindomethacin decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.isradipinesilodosin and isradipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.istradefyllineistradefylline will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of P-gp substrates in clinical trials. Consider dose reduction of sensitive P-gp substrates.ivacaftorivacaftor increases levels of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp; may significantly increase systemic exposure to sensitive P-gp substrates with a narrow therapeutic index.ketoconazoleketoconazole will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.ketoprofenketoprofen decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.ketorolacketorolac decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.ketorolac intranasalketorolac intranasal decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.labetalolsilodosin and labetalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.lapatiniblapatinib will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.levoketoconazolelevoketoconazole will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.lisinoprillisinopril, silodosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.lonafarniblonafarnib will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Lonafarnib is a weak P-gp inhibitor. Monitor for adverse reactions if coadministered with P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicities. Reduce P-gp substrate dose if needed.loratadineloratadine will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.lornoxicamlornoxicam decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.lovastatinlovastatin will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.lurasidonelurasidone increases effects of silodosin by Other (see comment). Use Caution/Monitor. Comment: Potential for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust dose of antihypertensive agent as needed.maravirocmaraviroc, silodosin. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.meclofenamatemeclofenamate decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.mefenamic acidmefenamic acid decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.meloxicammeloxicam decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.metoprololsilodosin and metoprolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.moexiprilmoexipril, silodosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.moxisylytemoxisylyte and silodosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.nabumetonenabumetone decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.nadololsilodosin and nadolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.naproxennaproxen decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.nebivololsilodosin and nebivolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.nefazodonenefazodone will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.nicardipinenicardipine will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.silodosin and nicardipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.nifedipinenifedipine will decrease the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.silodosin and nifedipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.nilotinibnilotinib will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.nisoldipinesilodosin and nisoldipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.nitroglycerin rectalnitroglycerin rectal, silodosin. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .oxaprozinoxaprozin decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.oxymetazoline topicaloxymetazoline topical increases and silodosin decreases sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Effect of interaction is not clear, use caution. Use Caution/Monitor.parecoxibparecoxib decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.penbutololsilodosin and penbutolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.perindoprilperindopril, silodosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.phenobarbitalphenobarbital will decrease the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.phenoxybenzaminephenoxybenzamine and silodosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.phentolaminephentolamine and silodosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.phenytoinphenytoin will decrease the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.pindololsilodosin and pindolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.piroxicampiroxicam decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.ponatinibponatinib increases levels of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.prazosinprazosin and silodosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.propranololsilodosin and propranolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. Increased risk of dizziness and orthostatic hypotension when silodosin is administered concurrently with antihypertensives.pseudoephedrinepseudoephedrine decreases effects of silodosin by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.quercetinquercetin will decrease the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.quinaprilquinapril, silodosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.ramiprilramipril, silodosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.ranolazineranolazine will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.rifampinrifampin will decrease the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.ritonavirritonavir will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.salicylates (non-asa)salicylates (non-asa) decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.salsalatesalsalate decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.saquinavirsaquinavir increases levels of silodosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Potential for increased toxicity. Use alternatives if available.sarecyclinesarecycline will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor for toxicities of P-gp substrates that may require dosage reduction when coadministered with P-gp inhibitors.simvastatinsimvastatin will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.sirolimussirolimus will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.sotalolsilodosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. Increased risk of dizziness and orthostatic hypotension when silodosin is administered concurrently with antihypertensives.St John's WortSt John's Wort will decrease the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.stiripentolstiripentol will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing the dose of P-glycoprotein (P-gp) substrates, if adverse reactions are experienced when administered concomitantly with stiripentol.sulfasalazinesulfasalazine decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.sulindacsulindac decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.tacrolimustacrolimus will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.tadalafiltadalafil increases effects of silodosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.terazosinsilodosin and terazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.timololsilodosin and timolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.tipranavirtipranavir increases levels of silodosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Use alternatives if available. Potential for increased toxicity. .tolfenamic acidtolfenamic acid decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.tolmetintolmetin decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.tolvaptantolvaptan will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.trandolapriltrandolapril, silodosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.trazodonetrazodone will decrease the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.tucatinibtucatinib will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities.vemurafenibvemurafenib increases levels of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.verapamilverapamil will increase the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.silodosin and verapamil both increase anti-hypertensive channel blocking. Use Caution/Monitor.zotepinesilodosin and zotepine both increase anti-hypertensive channel blocking. Use Caution/Monitor.Minor (7)brimonidinebrimonidine increases effects of silodosin by pharmacodynamic synergism. Minor/Significance Unknown.butcher's broomsilodosin, butcher's broom. Either decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown.ethanolsilodosin, ethanol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension, esp. in Asian pts.phenylephrinesilodosin, phenylephrine. Either decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown.phenylephrine POsilodosin, phenylephrine PO. Either decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown.tizanidinetizanidine increases effects of silodosin by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.treprostiniltreprostinil increases effects of silodosin by pharmacodynamic synergism. Minor/Significance Unknown.acebutololMonitor Closely (1)silodosin and acebutolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. Increased risk of dizziness and orthostatic hypotension when silodosin is administered concurrently with antihypertensives.aceclofenacMonitor Closely (1)aceclofenac decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.acemetacinMonitor Closely (1)acemetacin decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.aldesleukinMonitor Closely (1)aldesleukin increases effects of silodosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.alfuzosinMonitor Closely (1)alfuzosin and silodosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.amifostineMonitor Closely (1)amifostine, silodosin. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior